Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer

Mayo Clinic25 enrolled

Overview

This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Endometrial Carcinoma

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Eligibility

Sex: FEMALEMin age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Self-identified Black individuals ≥ 45 years with an intact uterus * Assigned female sex at birth * Experience with abnormal uterine or post-menopausal bleeding (defined as vaginal bleeding between periods, heavy vaginal bleeding, vaginal bleeding after menopause, and/or red, brown, or pink colored vaginal discharge after menopause) * Willing to participate in a 45-minute virtual interview Exclusion Criteria: * Previous or current diagnosis of endometrial cancer

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

RECRUITING

Outcomes

Primary Outcomes

Acceptability of vaginal fluid collection for a DNA-based early detection endometrial cancer test

Information collected during a 30-minute virtual interview using mostly open-ended questions. The interviews will be transcribed and reviewed by the study team to identity themes and create coding categories. Coding categories will be used to organize the data into subthemes. Results will be reported in aggregate. Aggregate results will be disseminated to participants if they elect to receive them.

Time frame: Baseline (30-minute virtual interview)

Central Contacts

Clinical Trials Referral Office

CONTACT

855-776-0015 mayocliniccancerstudies@mayo.edu

Kelly Gunderson

CONTACT

507-422-1892

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.